ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Takeda halts development of COVID-19 plasma therapy

Japanese drugmaker had counted on technology boost from Shire acquisition

A nurse attends to a patient suffering from COVID-19 at a hospital in Spain.    © Reuters

TOKYO -- Takeda Pharmaceutical has suspended the development of a plasma therapy for COVID-19 after it failed to show effectiveness in clinical trials, according to a Tuesday disclosure to investors.

Japan's top drugmaker, along with U.S.-based CSL Behring and other members of the CoVIg-19 Plasma Alliance, had been working on a new treatment for the coronavirus using antibodies taken from the plasma of recovered patients.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more